In Vitro echinocandin susceptibility of Aspergillus isolates from patients enrolled in the transplant-associated infection surveillance network

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 8, 2011, Pages 3944-3946

  Lockhart, Shawn R ^a   Zimbeck, Alicia J ^a   Baddley, John W ^b,c   Marr, Kieren A ^d   Andes, David R ^e   Walsh, Thomas J ^f,g   Kauffman, Carol A ^h   Kontoyiannis, Dimitrios P ⁱ   Ito, James I ^j   Pappas, Peter G ^k   Chiller, Tom ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b University of Alabama at Birmingham   (United States)

^c BIRMINGHAM VA MEDICAL CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

^h UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^j CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^k University of Alabama at Birmingham   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; MICAFUNGIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; ASPERGILLUS; GRAFT INFECTION; IN VITRO STUDY; INVASIVE ASPERGILLOSIS; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; HUMANS; LIPOPEPTIDES; MICROBIAL SENSITIVITY TESTS; TRANSPLANTATION;

EID: 79960295010     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00428-11     Document Type: Article

References (17)

1. Alastruey-Izquierdo, A., et al. 2010. In vitro activity of nine antifungal agents against clinical isolates of Aspergillus calidoustus. Med. Mycol. 48:97-102.
2. Alcazar-Fuoli, L., E. Mellado, A. Alastruey-Izquierdo, M. Cuenca-Estrella, and J. L. Rodriguez-Tudela. 2008. Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. Antimicrob. Agents Chemother. 52:1244-1251.
3. Antachopoulos, C., J. Meletiadis, T. Sein, E. Roilides, and T. J. Walsh. 2008. Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. Antimicrob. Agents Chemother. 52:321-328.
4. Ascioglu, S., et al. 2002. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin. Infect. Dis. 34:7-14.
5. Baddley, J. W., et al. 2009. Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J. Clin. Microbiol. 47:3271-3275.
6. Balajee, S. A., et al. 2009. Molecular identification of Aspergillus species collected for the Transplant-Associated Infection Surveillance Network. J. Clin. Microbiol. 47:3138-3141.
7. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi, 2nd ed. Approved standard M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Cuenca-Estrella, M., and J. L. Rodriguez-Tudela. 2010. The current role of the reference procedures by CLSI and EUCAST in the detection of resistance to antifungal agents in vitro. Expert Rev. Anti Infect. Ther. 8:267-276.
9. Kontoyiannis, D. P., et al. 2010. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin. Infect. Dis. 50:1091-1100.
10. Madureira, A., et al. 2007. Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin. Int. J. Antimicrob. Agents 30:551-554.
11. Messer, S. A., R. N. Jones, G. J. Moet, J. T. Kirby, and M. Castanheira. 2010. Potency of anidulafungin compared to nine other antifungal agents tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: results from the global SENTRY Antimicrobial Surveillance Program (2008). J. Clin. Microbiol. 48:2984-2987.
12. Pappas, P. G., et al. 2010. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin. Infect. Dis. 50:1101-1111.
13. Pfaller, M. A., et al. 2010. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist. Updat. 13:180-195.
14. Pfaller, M. A., et al. 2010. Wild-type minimum effective concentration distributions and epidemiologic cutoff values for caspofungin and Aspergillus spp. as determined by Clinical and Laboratory Standards Institute broth microdilution methods. Diagn. Microbiol. Infect. Dis. 67:56-60.
15. Pfaller, M. A., et al. 2009. In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method. J. Clin. Microbiol. 47:3323-3325.
16. Staab, J. F., J. N. Kahn, and K. A. Marr. 2010. Differential Aspergillus lentulus echinocandin susceptibilities are Fksp-independent. Antimicrob. Agents Chemother. 54:4992-4998.
17. Walsh, T. J., et al. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46:327-360.